Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
about
Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapiesApomorphine and the dopamine hypothesis of schizophrenia: a dilemma?Dopamine agonist therapy in advanced Parkinson's diseaseApomorphine: an underutilized therapy for Parkinson's disease.Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.Repairing the brain in Parkinson's disease: where next?Recent developments in the pharmacological treatment of Parkinson's disease.Clinical aspects and management of levodopa-induced dyskinesia.Parkinson's Disease and Its Management: Part 4: Treatment of Motor ComplicationsDopamine agonists in the treatment of Parkinson's disease.Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.Role of dopamine agonists in Parkinson's disease: an update.Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based reviewLevodopa in the treatment of Parkinson's disease: an old drug still going strong.Therapeutic options for continuous dopaminergic stimulation in Parkinson's diseaseDrugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.Therapies for dopaminergic-induced dyskinesias in Parkinson disease.Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.Subcutaneous infusions of apomorphine: a reappraisal of its therapeutic efficacy in advanced Parkinson's disease.Novel levodopa formulations in the treatment of Parkinson's disease.The role of subcutaneous infusion of apomorphine in Parkinson's disease.Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians.Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease.Advanced stages of PD: interventional therapies and related patient-centered care.Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets.Practical approaches to commencing device-assisted therapies for Parkinson's disease in Australia.Continuous levodopa for advanced Parkinson's disease.Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study.Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease.Pharmacological Insights into the Use of Apomorphine in Parkinson's Disease: Clinical Relevance.Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients.Apomorphine protects against MPTP-induced neurotoxicity in mice.Treatment of camptocormia with continuous subcutaneous infusions of apomorphine: 1-year prospective pilot study.
P2860
Q24672819-8F9C094C-63BD-4724-87D7-C6FC893F08BEQ28366409-58A50ACC-12A4-4BEA-9592-B7FB473CF3A9Q33636332-A351E49C-89B1-45A3-8118-F780CC7A07ECQ34048141-6FAEF36D-CC35-481D-91AD-0B9618EB2580Q34325365-66242D44-63B3-4112-81E7-3E52F97AE62BQ34580635-D3C23A23-401B-4ED3-88FC-19577E1AFD48Q35185761-F1D7B982-A797-40DB-9654-E8098D1A6947Q36022700-7A6C3CE6-24FA-47AF-BB49-8A09C8DCBC09Q36251899-3EE2EAA1-29C7-4DB3-B6A4-155F24AB1F55Q36390870-DE0F47BB-05D9-42EC-A15E-28DFFCCE21D5Q36703436-E1E6C76F-B02D-43A0-AA98-9EA9D7EA5E8FQ36972701-90C27503-2BF8-42C0-880D-9B4D639F45A3Q37115650-BBFF2FAE-E817-489A-8F5D-F78BA1B26AF4Q37302240-B7626DDF-A8FA-40BE-BD19-42B79A1696B5Q37790274-03EA9F9B-2A59-44DA-97A3-5E5793B87CF2Q37823337-07DB5CE6-DEFE-4540-89F3-12D154948677Q37831397-9CBD220E-D6D7-4939-A4D6-C5472D580586Q37890986-30770815-08DD-493A-A794-C24F5617E8D9Q37924626-499DFAB3-3C6C-42F3-852C-0D51B013566AQ37973462-F860BFEF-BF57-425F-B0A4-E27C409E1D76Q38070888-038EB106-BAAF-4208-B863-EC3FDAFE06B1Q38155589-C44A8CA7-02D3-4B15-94D7-FAF856AB1B72Q38178754-3D00EA55-10C8-4848-A3E8-71B321C97E98Q38219351-67F28BD1-3158-43B3-BB12-BAEDDAFCFFC8Q38237228-ADA80B94-3658-4E0C-BCFD-E3BE3BCB220EQ38284574-5A1D690B-2385-458E-A56D-0102B9287D1DQ38542180-56BB29C9-1A9D-4B2E-9468-8EBEDA8ED9D1Q38762256-43CE4CBD-A06F-4182-AAC5-69B1ED25EC8DQ38811387-11CC0305-A282-433F-B8A6-C7E9A1E2647DQ38822548-59E83932-FF79-4E79-8361-41F0CEA6E1EEQ39134831-F03C8AC1-99F3-46CF-BE7D-2D01D385A667Q41825026-9FE716FE-6603-476D-85AC-28325520E02FQ42164149-4BE1EA22-6E81-436A-AC8C-4429FBC2E4A2Q42688217-C5F16118-0532-4F03-AE8F-E3F6C43B3920Q43507658-5074BF57-9BDF-4793-9371-5FABDCE88E94Q47868277-2E46CAEF-E539-4174-8FC6-6BD60017D074Q47962428-B595AC4D-9398-463A-9F85-9DF4438CD5C5Q48064134-ADD0474A-D922-48E3-9B86-13ECC4909DD9Q48144127-39DBD857-A39C-4DA9-BDFF-069F3DBBC3E3Q48597778-E9CA3BE4-DEFD-4DAD-B68F-643B0F749A2F
P2860
Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Continuous subcutaneous waking ...... nesias in Parkinson's disease.
@ast
Continuous subcutaneous waking ...... nesias in Parkinson's disease.
@en
type
label
Continuous subcutaneous waking ...... nesias in Parkinson's disease.
@ast
Continuous subcutaneous waking ...... nesias in Parkinson's disease.
@en
prefLabel
Continuous subcutaneous waking ...... nesias in Parkinson's disease.
@ast
Continuous subcutaneous waking ...... nesias in Parkinson's disease.
@en
P2860
P921
P356
P1476
Continuous subcutaneous waking ...... nesias in Parkinson's disease.
@en
P2093
P2860
P304
P356
10.1136/JNNP.64.5.573
P407
P577
1998-05-01T00:00:00Z